Clinical and molecular characterization of HER2amplified-pancreatic cancer

Table 2 Clinicopathological characteristics of HER2-amplified PDAC

Patient	Her2 IHC score	HER2ratio	HER2count	Overall survival (months)	Cause of death	Pattern of recurrence					Comments
						Lung	Brain	Liver	Local	Peritoneal
1^a	3+	2.45	6	13.6	PDAC	-	ND	-	+	+	Laparotomy showed peritoneal and local recurrence
2	3+	7.5	13	43.5	COPD	-	ND	-	-	-	CT at 43 months showed no recurrence
3	3+	4.12	10	5.0	PDAC	-	ND	-	+	-	Local recurrence
4^b	2+	2.5	5.4	36.5	PDAC	+	ND	-	+	+	Ascites/pleural effusions, no liver metastases on CT
5	3+	4.38	8.1	18.6	PDAC	ND	ND	ND	ND	ND	Site not documented
6	2	3.56	7	10.1	PDAC	ND	ND	-	+	ND	R2 resection
7	3+	2.7	4.5	41.6	PDAC	ND	ND	-	+	+	No liver metastases on CT; peritoneal recurrence
8	2+	5.32	9	10.9	PDAC	+	ND	-	+	-	No liver metastases on CT
9^c,d	3+	2.95	6.2	35.0	PDAC	+	+	-	-	-	No liver metastases on CT
10^e	3+	2.86*	6.3	27.0	PDAC	+	ND	-	-	-	No liver metastases on CT

Abbreviations: + present; - absent; COPD chronic obstructive pulmonary disease; CT computed tomography; FISH fluorescence in situ hybridization; IHC immunohistochemistry; ND not determined; PDAC pancreatic ductal adenocarcinoma.
^aReceived adjuvant 5-fluouracil.
^bReceived adjuvant gemcitabine.
^cOnly case 9 received palliative chemotherapy (gemcitabine + erlotinib) and also received adjuvant gemcitabine.
^dCase that was whole genome sequenced.
^eCase 10 showed heterogeneous staining.

ISSN: 1756-994X